Breaking the 3 h barrier for treatment of acute ischaemic stroke

The Lancet Neurology

Volumn 7, Issue 11, 2008, Pages 981-982

  Donnan, Geoffrey A ^a   Davis, Stephen M ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; PLACEBO;

BLOOD CLOT LYSIS; BRAIN ANGIOGRAPHY; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CHRONOTHERAPY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE DURATION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG SAFETY; EARLY INTERVENTION; GROUPS BY AGE; HUMAN; LETTER; NERVE CELL; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANKIN SCALE; TREATMENT OUTCOME;

BRAIN ISCHEMIA; CLINICAL PROTOCOLS; CLINICAL TRIALS AS TOPIC; EARLY DIAGNOSIS; EMERGENCY MEDICAL SERVICES; FIBRINOLYTIC AGENTS; HUMANS; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 53449095870     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(08)70230-8     Document Type: Letter

References (12)

1. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 333 (1995) 1581-1587
2. Hacke W., Donnan G., Fieschi C., et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363 (2004) 768-774
3. Markus R., Reutens D.C., Kazui S., et al. Hypoxic tissue in ischaemic stroke: persistence and clinical consequences of spontaneous survival. Brain 127 (2004) 1427-1436
4. Barber P.A., Davis S.M., Darby D.G., et al. Absent middle cerebral artery flow predicts the presence and evolution of the ischemic penumbra. Neurology 52 (1999) 1125-1132
5. Hacke W., Kaste M., Bluhmki E., et al., for the ECASS Investigators. Thrombolysis with alteplase 3 to 4·5 hours after acute ischemic stroke. N Engl J Med 359 (2008) 1317-1329
6. Ingall T.J., O'Fallon W.M., Asplund K., et al. Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial. Stroke 35 (2004) 2418-2424
7. Wahlgren N., Ahmed N., Dávalos, et al., for the SITS investigators. Thrombolysis with alteplase 3-4·5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet (2008) 10.1016/S0140-6736(08)61339-2 published online Sept 15, 2008.
8. Davis S.M., Donnan G.A., Parsons M.W., et al. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol 7 (2008) 299-309
9. Albers G.W., Thijs V.N., Wechsler L., et al. Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol 60 (2006) 508-517
10. Whiteley W., Lindley R., Wardlaw J., and Sandercock P. Third international stroke trial. Int J Stroke 1 (2006) 172-176
11. Khatri P., Hill M.D., Palesch Y.Y., et al. Methodology of the interventional management of stroke III trial. Int J Stroke 3 (2008) 130-137
12. Saver J.L. Time is brain-quantified. Stroke 37 (2006) 263-266